Anna Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anna Shah has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Enrique Alvarez
Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA
2 shared publications - Aaron M. Carlson
Department of Neurology, University of Colorado School of Medicine, Aurora
1 shared publication - Amanda L. Piquet
Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States
1 shared publication - Andrew B. Wolf
University of Colorado Anschutz School of Medicine
1 shared publication Andrew J. Solomon
Department of Neurological Sciences, Lartner College of Medicine at the University of Vermont School, Burlington, VT, USA
1 shared publicationBenjamin Stewart
Saint Alphonsus Medical Group, Boise, ID, USA
1 shared publication
Latest Publications
- Open Access
- 1 April 2026
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 12 (2)
Absence of significant hematologic abnormalities in breastfed infants of mothers with multiple sclerosis treated with anti-CD20 therapies
Objectives: To assess hematologic abnormalities in breastfed infants of mothers with multiple sclerosis (MS) receiving anti-CD20 therapies. Methods: Breastfed infants with maternal anti-CD20 use were identified. Infant blood draws examined B-cell (CD19) and hematological counts. Results: Nine of 10 identified infants had CD19 percentages in ranges expected for age. One infant had CD19 levels below the 5 th percentile but was interpreted by their treating pediatrician as normal for age, with no increase in infections reported. Discussion: The absence of significant CD19 abnormalities in our cohort may indicate infant hematology safety. This may allow mothers MS to utilize anti-CD20 therapies while breastfeeding.
- 1 April 2026
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 12 (2)
Open AccessAbsence of significant hematologic abnormalities in breastfed infants of mothers with multiple sclerosis treated with anti-CD20 therapies
Objectives: To assess hematologic abnormalities in breastfed infants of mothers with multiple sclerosis (MS) receiving anti-CD20 therapies. Methods: Breastfed infants with maternal anti-CD20 use were identified. Infant blood draws examined B-cell (CD19) and hematological counts. Results: Nine of 10 identified infants had CD19 percentages in ranges expected for age. One infant had CD19 levels below the 5 th percentile but was interpreted by their treating pediatrician as normal for age, with no increase in infections reported. Discussion: The absence of significant CD19 abnormalities in our cohort may indicate infant hematology safety. This may allow mothers MS to utilize anti-CD20 therapies while breastfeeding.
- 1 August 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (4) , e200489
West Nile Virus Neuroinvasive Disease in Patients Treated With Anti-CD20 Therapies
The literature on severe West Nile virus (WNV) neuroinvasive disease (WNND) in patients treated with anti-CD20 therapies is limited. We systematically characterize cases of WNND in the tertiary academic UCHealth system. A retrospective cohort (January 2016 to January 2024) of patients with a validated diagnosis of WNND and anti-CD20 medication use was identified with electronic medical record query followed by individual chart review. We identified 25 patients; multiple sclerosis was the most common indication for anti-CD20 therapy in 13 patients (52%). Twenty-one patients (84%) presented with meningoencephalitis. CSF WNV IgM was positive in 5 of 21 patients (24%) who were tested while 13 of 14 tested patients (93%) had positive reverse-transcription PCR (RT-PCR) findings in the CSF. MRI demonstrated anomalies associated with WNND in 12 of 23 patients (52%) with available imaging. Intensive care unit admission was required in 8 patients (32%), and 12 patients (48%) were treated with intravenous immunoglobulin. Worsening of ≥1 point from pre-WNV baseline modified Rankin Scale (mRS) score to the 90-day postdischarge mRS score was seen in 18 patients (75%). Two patients (8%) died by 90 days. WNND leads to disability accrual in patients on B cell-depleting anti-CD20 therapies. Utilization of RT-PCR is important in optimizing diagnosis in this patient population because of limited sensitivity of the WNV-IgM testing commonly used in the general population.
- 1 August 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (4) , e200489
West Nile Virus Neuroinvasive Disease in Patients Treated With Anti-CD20 Therapies
The literature on severe West Nile virus (WNV) neuroinvasive disease (WNND) in patients treated with anti-CD20 therapies is limited. We systematically characterize cases of WNND in the tertiary academic UCHealth system. A retrospective cohort (January 2016 to January 2024) of patients with a validated diagnosis of WNND and anti-CD20 medication use was identified with electronic medical record query followed by individual chart review. We identified 25 patients; multiple sclerosis was the most common indication for anti-CD20 therapy in 13 patients (52%). Twenty-one patients (84%) presented with meningoencephalitis. CSF WNV IgM was positive in 5 of 21 patients (24%) who were tested while 13 of 14 tested patients (93%) had positive reverse-transcription PCR (RT-PCR) findings in the CSF. MRI demonstrated anomalies associated with WNND in 12 of 23 patients (52%) with available imaging. Intensive care unit admission was required in 8 patients (32%), and 12 patients (48%) were treated with intravenous immunoglobulin. Worsening of ≥1 point from pre-WNV baseline modified Rankin Scale (mRS) score to the 90-day postdischarge mRS score was seen in 18 patients (75%). Two patients (8%) died by 90 days. WNND leads to disability accrual in patients on B cell-depleting anti-CD20 therapies. Utilization of RT-PCR is important in optimizing diagnosis in this patient population because of limited sensitivity of the WNV-IgM testing commonly used in the general population.